Bayer and CrossBay Medical to develop ‘novel’ intrauterine system inserter

The partnership aims to boost the development and expansion of CrossBay’s existing CrossGlide technology, which is thought to have the potential to improve the intrauterine placement experience by limiting and reducing the discomfort women may experience during IUS insertion.

By removing these steps, the inserter has the potential to reduce procedure time necessary for healthcare professionals.

“As a leader in women’s healthcare, we are committed to further drive innovation for women worldwide that addresses their unmet medical needs,” said Juergen Eckhardt, member of the executive committee of Bayer’s Pharmaceuticals division and head of business development, licensing and open innovation.

“Partnering with CrossBay Medical has the potential to offer women an opportunity to consider the full range of contraceptive options available.”

Piush Vidyarthi, founder and CEO of CrossBay Medical, said: “We invented CrossGlide to help improve the insertion experience by creating a flexible system that follows the shape of a woman’s cervix.

“By doing this, we created a new paradigm for office-based procedures for both, women and healthcare providers.

“We are partnering with Bayer as a market leader in intrauterine contraception as we believe more women will be better served using the CrossGlide technology and therefore provided one of the most effective birth control options for consideration.”

CrossBay Medical works towards replacing older technologies with more innovative solutions that could empower physicians to deliver more gentle, compassionate care during uterine access procedures.

Pairing its technology with Bayer’s IUS portfolio is hoped to result in adapting the manufacturing process and industrialisation of the CrossGlide technology.